Ola Spjuth and Jordi Carreras Puigvert ready to robotise Uppsala Science Park

Phenaros Pharmaceuticals, the company founded by Ola Spjuth and Jordi Carreras Puigvert at the Department of Pharmaceutical Biosciences, have successfully completed a pre-seed funding round. With these resources, Phenaros Pharmaceuticals – based on progress achieved by the Pharmaceutical Bioinformatics research team – is preparing to launch their new laboratory at Uppsala Science Park.

“We are thrilled to have secured this pre-seed funding, which is a testament to the potential of our platform and the strength of our team – and above all, gives us the resources to accelerate the establishment of our platform with a focus on drug discovery and safety profiling,” states Ola Spjuth, CEO of Phenaros Pharmaceuticals and Professor at Uppsala University.

Phenaros Pharmaceuticals will, by integrating artificial intelligence, phenomics and robotised high-throughput experimentation, accelerate drug discovery and assess the potential of new drug candidates. The potential market is waiting, and already ahead of finializing its facilities, Phenaros has both paying customers and received the UU Innovation Attractive Innovation Project Award.

“Our research team inaugurated our first robotised laboratory at Uppsala’s Biomedical Center in 2021 before opening the doors to Europe's first robotised course laboratory in 2022. Now we are investing our experiences into Phenaros Pharmaceuticals and expect to enter full operational mode already this spring,” says Ola Spjuth.

text: Magnus Alsne, photo: Mikael Wallerstedt a o